drugset / Trial / NCT05240261

Sleep Disorders in Chronic Kidney Disease Patients

NCT05240261

Phase 1 Unknown 60 enrolled Assiut University
RandomizedSingle-groupOpen-labelOther

Summary

1. Asses sleep disorders in CKD patients and those on haemodialysis and related complications ( uncontrolled blood pressure,glomerular filtration rate (GFR) ,proteinuria and psychological disturbance) 2. Asses effect of hypnotics or sedations for 3 month in improvement those complications after taking treatment .

Timeline

Start
2022-05-01
Primary completion
2024-05-01
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 25 mg